FIGURE 4.

Proportion of patients in (A) the tofacitinib 5 mg b.d. group, and (B) the tofacitinib 10 mg b.d. group, who achieved PMS remission, ‘as observed’ and with NRI‐LOCF, in OCTAVE Open (FAS). Patients in remission at the start of OCTAVE Open were assigned to tofacitinib 5 mg b.d.; all other patients were assigned to tofacitinib 10 mg b.d. b.d., twice daily; FAS, full analysis set; N1, number of patients in the specified category with non‐missing data; n, number of patients with the specified response within the given category; NRI‐LOCF, non‐responder imputation was applied after a patient discontinued and last observation carried forward imputation after a patient advanced to a subsequent study up to the visit they would have reached if they had stayed in the study. Non‐responder imputation was applied for intermittent missing data; PMS, partial Mayo score